Moderna (MRNA) Receivables (2017 - 2026)
Moderna (MRNA) posted quarterly Receivables of $160.0 million for Q2 2026, down 47.88% year-over-year from $307.0 million in Q2 2025, and down 33.88% on a QoQ basis from $242.0 million in Q1 2026.
Moderna (MRNA) Receivables (2017 - 2026) Analysis & Trends
Moderna has reported Receivables for 10 years, with the latest figure at $160.0 million in Q2 2026.
- Receivables for Q2 2026 came in at $160.0 million, down 47.88% year-over-year; the trailing twelve-month figure through Jun 2026 was $160.0 million (down 47.88% YoY), and the FY2025 annual result was $410.0 million, down 45.84% from the prior year.
- Receivables declined to $160.0 million in Q2 2026, from $242.0 million in the prior quarter.
- Over five years, Receivables peaked at $3.2 billion in Q1 2022 and troughed at $160.0 million in Q2 2026.
- A 5-year average of $1.3 billion and a median of $969.5 million in 2023 frame the typical range for Receivables.
- The widest annual swing landed in 2023, when Receivables tumbled 89.3%; it then jumped 86.39% in 2024.
- A 5-year view of Receivables shows it stood at $1.4 billion in 2022, then increased by 13.62% to $1.6 billion in 2023, then plunged by 53.93% to $757.0 million in 2024, then sank by 45.84% to $410.0 million in 2025, then plunged by 60.98% to $160.0 million in 2026.
- Per Business Quant data, the three most recent Receivables figures were $160.0 million in Q2 2026, $242.0 million in Q1 2026, and $410.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn | 160.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 160.00 Mn |
| Mar 31, 2026 | 242.00 Mn |
| Dec 31, 2025 | 410.00 Mn |
| Sep 30, 2025 | 2.06 Bn |
| Jun 30, 2025 | 108.00 Mn |
| Mar 31, 2025 | 302.00 Mn |
| Dec 31, 2024 | 757.00 Mn |
| Sep 30, 2024 | 2.78 Bn |
| Jun 30, 2024 | 219.00 Mn |
| Mar 31, 2024 | 484.00 Mn |
| Dec 31, 2023 | 1.64 Bn |
| Sep 30, 2023 | 1.92 Bn |
| Jun 30, 2023 | 294.00 Mn |
| Mar 31, 2023 | 1.18 Bn |
| Dec 31, 2022 | 1.45 Bn |
| Sep 30, 2022 | 2.75 Bn |
| Jun 30, 2022 | 2.75 Bn |
| Mar 31, 2022 | 3.21 Bn |
| Dec 31, 2021 | 3.20 Bn |
| Sep 30, 2021 | 3.14 Bn |